Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28350691 | 1.00 | FUCA1 (0.32) | FUCA1ALOX15 | |
| SCHEMBL27484975 | 1.00 | FUCA1 (0.32) | FUCA1ALOX15 | |
| SCHEMBL27487583 | 0.79 | EP300 (0.30) | — | |
| SCHEMBL27469787 | 0.78 | ALOX15 (0.35) | ALOX15 | |
| SCHEMBL5042450 | 0.78 | ALOX15 (0.35) | ALOX15 | |
| SCHEMBL5042658 | 0.77 | ALOX15 (0.33) | ALOX15 | |
| Hydrochloric Acid SCHEMBL27471279 | 0.77 | ALOX15 (0.34) | ALOX15 | |
| SCHEMBL5042569 | 0.75 | USP2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL27548749 | 0.74 | CYP1A2 (0.41) | ALOX15 | |
| SCHEMBL197847 | 0.73 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3884486-B2 | — | — | 2007-02-21 | — | — | JP | claimed |
| EP-1554237-A4 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT INC (US) | 2006-11-02 | — | — | EP | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| CN-1675165-A | Method for synthesizing acyloxyalkyl derivatives of GABA analogs | XENOPORT INC (US) | 2005-09-28 | — | — | CN | claimed |
| EP-1554237-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | Xenoport, Inc. (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2005018622-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018621-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043345-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043406-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| WO-2003104184-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| US-20020032235-A1 | Anti-inflammatory method | SCHRIER DENIS (US) | 2002-03-14 | — | — | US | claimed |
| JP-2002506449-A | — | — | 2002-02-26 | — | — | JP | claimed |
| US-6329429-B1 | ADMINISTERING ANTI-INFLAMMATORY COMPOUND COMPRISING CYCLIC AMINO ACID OR ITS DERIVATIVE TO THERAPY | WARNER-LAMBERT COMPANY | 2001-12-11 | — | — | US | claimed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
| US-20250375403-A1 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL | PLEOPHARMA INC (US) | 2025-12-11 | — | — | US | disclosed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| EP-1608357-A4 | TREATING OR PREVENTING HOT FLASHES USING PRODRUGS OF GABA ANALOGS | XENOPORT INC (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1471909-A4 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | ENDO PHARMACEUTICALS INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| CN-1878546-A | Combination comprising an alpha-2 delta ligand and an SSRI and/or SNRI for the treatment of depression and anxiety | WARNER LAMBERT CO (US) | 2006-12-13 | — | — | CN | disclosed |
| US-7138542-B2 | Method of treating tinnitus | WARNER LAMBERT COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1554237-A4 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060167032-A1 | Pharmaceutical composition and method for treating disorders of the central nervous system | ENDO PHARMACEUTICALS INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1677812-A2 | TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS | Xenoport, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1675582-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | Warner-Lambert Company LLC (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060100281-A1 | Method of treating tinnitus | DOOLEY DAVID J | 2006-05-11 | — | — | US | disclosed |
| CN-1726015-A | Alpha 2 delta ligands for different pharmaceutical uses | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1608357-A2 | TREATING OR PREVENTING HOT FLASHES USING PRODRUGS OF GABA ANALOGS | Xenoport, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1675165-A | Method for synthesizing acyloxyalkyl derivatives of GABA analogs | XENOPORT INC (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1572172-A1 | ALPHA2DELTA LIGANDS FOR DIFFERENT PHARMACEUTICAL USES | WARNER-LAMBERT COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1554237-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | Xenoport, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| CN-1642547-A | Pharmaceutical composition and method for treating disorders of the central nervous system | ENDO PHARMACEUTICALS INC (US) | 2005-07-20 | — | — | CN | disclosed |
| CN-1635887-A | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | WARNER LAMBERT CO (US) | 2005-07-06 | — | — | CN | disclosed |
| EP-0994704-B1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER LAMBERT CO (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1625393-A | Alpha 2 delta ligands to treat tinnitus | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | CN | disclosed |
| US-6887902-B2 | Anti-inflammatory method using gamma-aminobutyric acid (GABA) analogs | WARNER-LAMBERT COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| WO-2005027850-A2 | TREATING OR PREVENTING RESTLESS LEGS SYNDROME USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005025563-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1515709-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | Warner-Lambert Company LLC (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | ARNERIC STEPHEN P (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005018622-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018621-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20050043406-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| EP-1480639-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1471909-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Endo Pharmaceuticals Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1469841-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004089289-A2 | TREATING OR PREVENTING HOT FLASHES USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040132636-A1 | Pharmaceutical uses for alpha2delta ligands | DOOLEY DAVID JAMES (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004054559-A1 | ALPHA2DELTA LIGANDS FOR DIFFERENT PHARMACEUTICAL USES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| EP-1221950-B1 | SYNERGISTIC COMBINATIONS OF AN NK1 RECEPTOR ANTAGONIST AND A GABA STRUCTURAL ANALOG | WARNER LAMBERT CO (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004002462-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING TTENTION DEFICIT HYPERACTIVITY DISORDER | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | DOOLEY DAVID JAMES (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003104184-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | TAYLOR CHARLES PRICE (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003061656-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | ENDO PHARMACEUTICALS INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| CN-1387434-A | Synergistic combination of NK1 receptor antagonists and GABA structural analogs | WARNER LAMBERT CO (US) | 2002-12-25 | — | — | CN | disclosed |
| WO-2001024792-A9 | SYNERGISTIC COMBINATIONS OF AN NK1 RECEPTOR ANTAGONIST AND A GABA STRUCTURAL ANALOG | WARNER LAMBERT CO (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1233766-A1 | USE OF SYNERGISTIC COMBINATIONS OF A NK 1? RECEPTOR ANTAGONIST AND A GABA ANALOG IN PSYCHIATRIC DISORDERS | WARNER-LAMBERT COMPANY (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1221950-A1 | SYNERGISTIC COMBINATIONS OF AN NK 1? RECEPTOR ANTAGONIST AND A GABA STRUCTURAL ANALOG | WARNER-LAMBERT COMPANY (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020032235-A1 | Anti-inflammatory method | SCHRIER DENIS (US) | 2002-03-14 | — | — | US | disclosed |
| US-6329429-B1 | ADMINISTERING ANTI-INFLAMMATORY COMPOUND COMPRISING CYCLIC AMINO ACID OR ITS DERIVATIVE TO THERAPY | WARNER-LAMBERT COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001024791-A1 | USE OF SYNERGISTIC COMBINATIONS OF A NK1 RECEPTOR ANTAGONIST AND A GABA ANALOG IN PSYCHIATRIC DISORDERS | WARNER-LAMBERT COMPANY (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001024792-A1 | SYNERGISTIC COMBINATIONS OF AN NK1 RECEPTOR ANTAGONIST AND A GABA STRUCTURAL ANALOG | WARNER-LAMBERT COMPANY (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885ALOX15 3671/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | FUCA1 1377/4885ALOX15 2410/4885 |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885ALOX15 3671/4885 |
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | SLC6A2, SLC18A2, ADRA2C | FUCA1 1329/4885ALOX15 2825/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | FUCA1 521/4885ALOX15 1587/4885 |
| US-20060100281-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRB2 | FUCA1 1973/4885ALOX15 2253/4885 |
| US-20060167032-A1 | Pharmaceutical composition and method for treating disorders of the central nervous system | GRIN3A, PMP22, GRIN3B | FUCA1 1444/4885ALOX15 2973/4885 |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | CACNG2, GABRB2, CACNG4 | FUCA1 2867/4885ALOX15 2761/4885 |
| US-20020032235-A1 | Anti-inflammatory method | GABRB2, GABRB1, GABRB3 | FUCA1 2640/4885ALOX15 195/4885 |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885ALOX15 3671/4885 |
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885ALOX15 3671/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | FUCA1 521/4885ALOX15 1587/4885 |
| US-20040132636-A1 | Pharmaceutical uses for alpha2delta ligands | ADRA1D, OPRD1, ADRA1A | FUCA1 812/4885ALOX15 3773/4885 |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | GABRB2, GABBR1, GABBR2 | FUCA1 2920/4885ALOX15 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.